Saniona and Medix sign development and commercialisation agreement for tesofensine and Tesomet in Mexico and Argentina
Saniona, a leading biotech company in the field of ion channels, today announces that it has entered into a drug development and commercialisation collaboration with Productos Medix, S.A de S.V (Medix). Medix is granted exclusive rights to develop and commercialise tesofensine and Tesomet in Mexico and Argentina. Medix will finance and be responsible for the clinical development and regulatory filings in the two countries. Medix intends to initiate Phase 3 clinical studies for tesofensine for obesity later this year. Saniona retains all rights to tesofensine and Tesomet in the rest of the world. Medix will pay Saniona an upfront payment of US$ 1.25 million (about SEK 10.5 million), regulatory milestone payments, and double-digit royalties on product sales.
“We are very excited about the possibility of developing and introducing tesofensine and Tesomet to the market in Mexico and Argentina for Saniona. We are planning to initiate Phase 3 clinical trials for tesofensine, which has shown outstanding efficacy and good tolerability in Phase 2 clinical trials in obesity, a severe health problem in Mexico. We also intend to initiate Phase 2 and Phase 3 clinical studies with Tesomet, which is considered to have additional benefits for certain patients and may potentially expand the market for obesity and its comorbidities such as type 2 diabetes,” says Carlos López Patán, CEO of Medix.
Jørgen Drejer, CEO of Saniona sees great opportunities in the collaboration. “This collaboration is completely in line with our strategy of combining high ambitions with a low burn rate. It brings us closer to the market and represents a significant leap for Saniona. Medix has demonstrated a strong commitment to develop and commercialise novel treatment paradigms for overweight and obesity where they have been market leaders in Mexico for several years. By initiating Phase 3 clinical trials for tesofensine in obesity, Medix may potentially be the first company to introduce one of Saniona´s product candidates to the market, which may lead to a stable income stream to Saniona through royalties on product sales in Mexico and Argentina in the medium term. Moreover, Saniona will have the exclusive rights to use the clinical data developed by Medix in the rest of world,” says Jørgen Drejer, CEO of Saniona.
For more information, please contact
Thomas Feldthus, EVP and CFO, Saniona, Mobile: +45 2210 9957, E-mail: firstname.lastname@example.org
Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatment of pain. The company has a significant portfolio of potential drug candidates at pre-clinical and clinical stage. The research is focused on ion channels, which makes up a unique protein class that enables and controls the passage of charged ions across cell membranes. Saniona has ongoing collaboration agreements with Upsher-Smith Laboratories, Inc., Productos Medix, S.A de S.V and Saniona’s Boston based spinout Ataxion Inc., which is financed by Atlas Venture Inc. and Biogen Idec Inc. Saniona is based in Copenhagen, Denmark, where it has a research center of high international standard. Saniona is listed at AktieTorget since April 2014 and has about 3,000 shareholders. The company’s share is traded under the ticker SANION. Read more at www.saniona.com.
About Productos Medix, S.A de S.V (Medix)
Medix is a Mexican pharmaceutical company established in 1956. Medix is primarily focused on treatment of overweight and obesity. The company is the market leader for treatment of overweight and obesity in Mexico where it offers the most comprehensive product and service line. Medix’s leading product for treatment of overweight and obesity is among the top ten pharmaceutical products in Mexico overall. Medix has earned several recognitions for its social responsibility through its participation in philanthropic programs for the benefit of the Mexican population and for its educational efforts involving thousands of doctors in Mexico. The company has subsidiaries in Argentina and certain other South American countries.
About overweight and obesity in Mexico
Mexico ranks the most obese country in the world. It is estimated that more than 70% of the 128 million Mexicans are overweight and that more than 30% are clinical obese. Since the 1990s, fat has become the principal source of energy in the Mexican diet and it is assumed that the consumption of highly processed food will continue increasing. As a consequence, Mexico has seen the same kind of health issues that other countries with overweight populations have. Standardized mortality rates (SMR) for diabetes, acute myocardial infarction (AMI), and hypertension have increased dramatically. As of 2012, diabetes - associated with obesity - was the largest single killer in Mexico.
Obesity is characterised by severe excess weight in the form of fat and is defined on the basis of a measure referred to as Body Mass Index (BMI). A BMI of more than 30 is referred to as clinical obesity, while a BMI of 25-30 expresses excess weight. Obesity is a serious clinical condition that involves a notably increased risk of cardiovascular diseases and the development of type 2 diabetes. According to the World Health Organization, obesity has reached epidemic proportions worldwide with more than one billion overweight adults of whom at least 300 million are clinically obese. Today, there is a strong medical need for more effective treatment options for obesity.
Tesofensine, a monoamine uptake inhibitor, is focused on obesity. Tesofensine has been evaluated in Phase 1 and Phase 2 human clinical studies with the aim of investigating treatment potential with regards to obesity, Alzheimer’s disease and Parkinson’s disease. Tesofensine demonstrated strong weight reducing effects in Phase 2 clinical studies in obese patients. In general, tesofensine has been administered to more than 1,200 patients and is well tolerated.
Mode of Action – Tesofensine potentiate dopamine
Pathological overeating and obesity can be caused by decreased dopamine function in the reward centre of the brain. Dopamine transporter proteins are inhibited by tesofensine, so the dopamine receptors are stimulated for a longer period of time after activation and the brain’s reward system is amplified. With a similar mechanism of action tesofensine also increases levels of two other monoamines, serotonin and noradrenaline.
Each of these transmitters exert an important function on appetite and metabolism at different locations in the brain. Dopamine acts in the nucleus accumbens of the forebrain to modulate reward and the “pleasure”-feeling of food. The two other transmitters act in the hypothalamus to increase metabolism and reduce appetite.
The unique efficacy of tesofensine in obesity may be explained by reversal of blunted dopamine response in obese patients. In obese individuals the brain centre (striatum) controlling consummatory food reward dopamine receptors are reduced relative to lean individuals. It has been found that in the relevant brain region more than 70% of obese individuals have a blunted dopamine response to food intake.
Clinical Programs - Tesofensine has produced superior weight loss data.
The clinical Phase 2b trial (TIPO-1) reported in The Lancet showed levels of weight loss over a six month period that were of high clinical relevance and highly competitive to other approaches. Patients lost an average of 12.8 kg on a 1 mg dose, 11.3 kg on a 0.5 mg dose and 6.7 kg on a 0.25 mg dose compared with a 2.2 kg loss in the placebo group. All participants were instructed to follow a diet with a 300 kcal deficit and to increase their physical activity gradually to 30-60 minutes of exercise per day. Of the patients receiving 0.5 mg daily, considered the relevant therapeutic dose, 87% of the patients (58% versus placebo) achieved more than 5% weight loss and 53% of the patients (46% versus placebo) achieved a weight loss of more than 10% after 6 months follow up.
There has also been reported interim results from a 48-week, open-label extension trial (TIPO-4) in which 140 patients who completed the 24-week Phase 2b trial (TIPO-1) were re-enrolled after an average of three months’ wash-out. All were then treated with 0.5 mg tesofensine once daily but up-titration to 1 mg once daily was allowed in the first 24 weeks of the extension study. The 24-week interim results for those who were previously treated with 0.5 mg tesofensine in TIPO-1 showed a total mean weight loss of between 13 kg and 14 kg over 48 weeks of treatment. Furthermore, TIPO-4 confirmed the TIPO-1 results since the patients who were previously treated with placebo lost approximately 9 kg in the first 24 weeks of the TIPO-4 study.
Tesomet is a fix-dosed combination of tesofensine and metoprolol, which Saniona plans to position for treatment of type 2 diabetes. In addition to obesity, tesofensine has also the potential to reverse the progression of type 2 diabetes by reducing liver fat. The market for type 2 diabetes is estimated to grow from US $ 23 billion in 2014 to 43 billion USD 2023 due to the increasing problems with obesity. Type 2 diabetes is considered as a progressive chronic disease today. However, recent published research concludes that type 2 diabetes is reversible and that large patient populations may undergo long-term remission if they achieve a substantial weight loss through reduced food consumption.
Saniona believes that tesofensine represents an interesting new treatment option for type 2 diabetes, which not only may be used in parallel with existing treatments, but also may offer potentially long-term remission in many patients by contributing to a substantial weight loss. In general, tesofensine has been well tolerated in human clinical studies. However, an increase in heart rate has been observed at therapeutic relevant doses of tesofensine. Patent applications have been filed in respect of the combination tesofensine and a beta blocker. Saniona has received notice of allowance of a U.S. patent application, which includes a combination of tesofensine and metoprolol and which can provide protection in the United States until 2033, if issued. The combination product is covered by other recent Saniona patent applications with broad geographic coverage. Saniona has recently published new results from datamining of previous clinical studies, which show that tesofensine improved glycaemic parameters in prediabetes individuals participating in a Phase 2 obesity study and that metoprolol blunts the increase in heart rate caused by tesofensine in volunteers in a Phase 1 study. Saniona expects to initiate a Phase 2a study during the first half of 2016 for Tesomet in type 2 diabetes patients.